Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis
Conditions
Cholangitis, Sclerosing
What is the purpose of this trial?
The purpose of this research study is to determine whether the combination of UDCA and ATRA taken for 3 months will improve laboratory tests of liver and bile duct inflammation in patients with PSC. Our hypothesis is that a combination of these medications will improve the liver inflammatory tests in these patients, specifically a reduction in alkaline phosphatase (AP) by at least 30%.
Participation Guidelines
- Age:
- 18 Years - 80 Years
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Mayo Clinic
Yale University - Dates:
- October 2011
- Last Updated:
- October 19, 2011
- Study HIC#:
- 1012007734
Clinicaltrials.gov ID: NCT01456468
For more information about this trial, contact:
David N Assis, MD
203-785-5279
david.assis@yale.edu
James L Boyer, MD
203-785-5279
james.boyer@yale.edu
Investigator
James Boyer, MD
Principal Investigator
